In parallel, we are investigating novel peptide-based vectors that target cytoskeletal proteins aberrantly expressed during malignant transformation, such as Vimentin-3, as an alternative strategy for intracellular delivery in receptor-negative or triple-negative breast cancers. This evidence concerns the gene DNM2 and triple-negative breast carcinoma.